Olanzapine

Abstract

Polyuria and polydipsia: case report In a report, an 8-year-old boy and a 13-year-old boy were described, who developed polyuria/polydipsia during treatment with olanzapine for autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) [routes and time to reactions onset not stated]. An 8-year-old boy with ASD and DHD received trials of various drugs including risperidone, methylphenidate, aripiprazole and quetiapine for agitation, irritability and hyperactivity. During curfew (for COVID-19 pandemic), his symptoms worsened. Hence, his treatment was changed to olanzapine 10 mg/day. Within 1 week after the initiation of olanzapine, his mother reported that he was urinating around 6–8 times an hour. Due to the pandemic, the information was obtained via telephone conversations and video recordings. Fluid restriction was applied, but no improvement was observed. Thereafter, olanzapine was tapered and stopped, following which polyuria/polydipsia recovered. Polyuria/polydipsia was thought likely to be related to olanzapine. At 4 months follow-up, no recurrence was observed. A 13-year-old boy, who had ASD and ADHD, had been receiving olanzapine 10 mg/day for 10 months (the only agent that improved his symptoms). During COVID-19 pandemic, his symptoms deteriorated. Hence, his olanzapine dose was increased to 15 mg/day. One day after increasing the dose of olanzapine, he was admitted to the emergency department with agitation, seizures, polyuria/polydipsia and low serum sodium level. The fluid intake was restricted, and olanzapine dose was decreased to previous dose of 10 mg/day. Polyuria/polydipsia was thought likely to be related to olanzapine. On day 3, he was discharged when his sodium level normalised and polyuria/polydipsia resolved.